NHS Trusts gain access to Galen, Ibex’s multi-tissue AI platform, which empowers pathologists with improved diagnostic accuracy and efficiency
Tel Aviv, Israeland LONDON, December 7, 2022 /PRNewswire/ — Capricorn Medical Analysis (Ibex), the leader in AI-enabled cancer diagnostics, and Source LDPath, part of Source BioScience (Source), a leading international provider of integrated state-of-the-art laboratory services and products, today announced an agreement to expand the use of artificial intelligence (AI) across Source’s pathology network.
The expansion builds on Ibex’s previous association with LDPath, which was acquired by Source earlier this year to create Source LDPath, one of the UK’s largest private providers of cellular and digital pathology services. Deployment will include new AI-powered tools to diagnose multiple tissue types and provide pathologists with improved diagnostic accuracy and efficiency.
Across the UK, patients are facing significant delays in getting their cancer diagnosed due to a shortage of pathologists, an increase in cancer cases, a growing workload on pathology departments and a significant backlog of cases in the wake of the pandemic. Despite advances, around 275,000 women and 100,000 men undergo a prostate biopsy in the UK each year1.2NHS pathology services often miss their reporting targets, leading to delays in starting treatment, which can impact patient survival rates.
There is clearly a growing need for automated decision support solutions and tools that help pathologists detect cancer faster and with the highest accuracy. Ibex’s Galen™ platform will be made available to the entire Source network, which includes more than 200 pathologists who will use Ibex’s AI-powered workflows integrated with an in-house developed LIS and reporting system.
Ibex’s Galen solution suite is the first and most widely adopted AI technology in pathology to be implemented in routine clinical practice in…
[ad_2]
Source story
